Clinical Trial Update: Efficacy and Safety of 100IR, 300IR, 500IR Sublingual House Dust Mite Tablets in Allergic Rhinitis Environment Exposure Chamber Model [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the efficacy and safety of three doses of sublingual house dust mite tablets for allergic rhinitis; results completed and posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis

Drugs mentioned

• Sublingual House Dust Mite Tablet (100IR/300IR/500IR) (house dust mite sublingual immunotherapy tablet)

Snippet

Sponsor: Stallergenes Greer | Conditions: Allergic Rhinitis Due to House Dust Mite | Phase 2 | Status: COMPLETED | Results posted: 2025-02-04